DoW Breast Cancer, Transformative Breast Cancer Consortium Development Award
Dept. of the Army -- USAMRAA
Funding Amount
$140,000 total
Deadline
July 8, 2026
37 days left
Grant Type
federal
Overview
DoW Breast Cancer, Transformative Breast Cancer Consortium Development Award
Summary: The fiscal year 2026 (FY26) Breast Cancer Research Program (BCRP) Transformative Breast Cancer Consortium Development Award provides successful applicants the time and resources needed to bring investigators and breast cancer consumer advocates together to establish a consortium framework and conduct preliminary research in support of an application to a future, full BCRP Transformative Breast Cancer Consortium Award (pending availability of funds). All applications must address at least one of the FY26 BCRP overarching challenges or provide adequate justification for exception. Distinctive Features: · This is a development award and is a separate award mechanism from the full FY26 BCRP Transformative Breast Cancer Consortium Award (HT942526BCRPTBCCA). For FY26, investigators may be named as Consortium Director on an application submitted to either (but not both) of these award mechanisms. · Breast cancer consumer advocates must be active participants in the development and execution of the FY26 BCRP TBCCDA.
Details
- Agency: Dept. of the Army -- USAMRAA
- Department: Department of Defense
- Opportunity #: HT942526BCRPTBCCDA
- Total Funding: $140,000
- Expected Awards: 1
- Instrument: cooperative_agreement
Eligibility
Eligible Applicant Types
Focus Areas & Funding Uses
Fields of Work
Categories
Browse similar grants by category
Related Grants
Similar grants from this funder and related organizations
Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R01 Clinical Trial Not Allowed)
National Institutes of Health
Amount
Up to $350,000
Deadline
September 7, 2026
Research Projects to Enhance Applicability of Mammalian Models for Translational Research (R01 Clinical Trial Not Allowed)
National Institutes of Health
Amount
Up to $499,000
Deadline
September 7, 2026
Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R21 Clinical Trials Not Allowed)
National Institutes of Health
Amount
Up to $200,000
Deadline
September 7, 2026
Specialized Programs of Research Excellence (SPOREs) in Human Cancers for Years 2024, 2025, and 2026 (P50 Clinical Trial Required)
National Institutes of Health
Amount
Varies
Deadline
September 25, 2026
Innovative Research in Cancer Nanotechnology (IRCN; R01 Clinical Trial Not Allowed)
National Institutes of Health
Amount
Up to $475,000
Deadline
Closed
Understanding Expectancies in Cancer Symptom Management (R01 Clinical Trial Required)
National Institutes of Health
Amount
Varies
Deadline
Closed
Ready to apply for DoW Breast Cancer, Transformative Breast Cancer Consortium Development Award?
Grantable helps you assess fit, draft narratives, and track deadlines — so you can submit stronger applications, faster.
You found DoW Breast Cancer, Transformative Breast Cancer Consortium Development Award. Now let's win it.